rs1162371435
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_004364.5(CEBPA):āc.715C>Gā(p.Pro239Ala) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000649 in 1,154,776 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_004364.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CEBPA | NM_004364.5 | c.715C>G | p.Pro239Ala | missense_variant | 1/1 | ENST00000498907.3 | NP_004355.2 | |
CEBPA | NM_001287424.2 | c.820C>G | p.Pro274Ala | missense_variant | 1/1 | NP_001274353.1 | ||
CEBPA | NM_001287435.2 | c.673C>G | p.Pro225Ala | missense_variant | 1/1 | NP_001274364.1 | ||
CEBPA | NM_001285829.2 | c.358C>G | p.Pro120Ala | missense_variant | 1/1 | NP_001272758.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CEBPA | ENST00000498907.3 | c.715C>G | p.Pro239Ala | missense_variant | 1/1 | 6 | NM_004364.5 | ENSP00000427514.1 | ||
ENSG00000267727 | ENST00000587312.1 | n.356+66G>C | intron_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000202 AC: 3AN: 148564Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.0000716 AC: 72AN: 1006212Hom.: 0 Cov.: 30 AF XY: 0.0000671 AC XY: 32AN XY: 476584
GnomAD4 genome AF: 0.0000202 AC: 3AN: 148564Hom.: 0 Cov.: 32 AF XY: 0.0000276 AC XY: 2AN XY: 72394
ClinVar
Submissions by phenotype
Acute myeloid leukemia Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 24, 2023 | This sequence change replaces proline, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 239 of the CEBPA protein (p.Pro239Ala). This variant is present in population databases (no rsID available, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with CEBPA-related conditions. ClinVar contains an entry for this variant (Variation ID: 526802). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CEBPA protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jul 25, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 05, 2024 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jan 08, 2021 | DNA sequence analysis of the CEBPA gene demonstrated a sequence change, c.715C>G, in exon 1 that results in an amino acid change, p.Pro239Ala. This sequence change does not appear to have been previously described in individuals with CEBPA-related disorders and has been described in the gnomAD database in two individuals with an overall population frequency of 0.0075% (dbSNP rs1162371435). The p.Pro239Ala change affects a moderately conserved amino acid residue located in a domain of the CEBPA protein that is known to be functional. The p.Pro239Ala substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Pro239Ala change remains unknown at this time. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 12, 2023 | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at